EpilepsyGTx

About EpilepsyGTx

EpilepsyGTx is a late preclinical-stage biotech company focused on developing cutting-edge gene therapies to transform the management of focal refractory epilepsy (FRE), with the goal of making patients seizure-free.

Products & Services

EPY201:Lead gene therapy program for focal refractory epilepsy, aimed at achieving seizure freedom through targeted delivery to the seizure focus.

Specialties

Gene Therapy Epilepsy Research Focal Refractory Epilepsy (FRE) Management

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 33000000 MR: - FA: $33 million FAN: 33000000	D: 2025-12-10 FD: 2025-12-10	3 investors
2	RT: Seed T: - FT: Seed	A: 10000000 MR: - FA: $10 million FAN: 10000000	D: 2024-06-24 FD: 2024-06-24	2 investors

Series A Latest

2025-12-10

$33.0M

3 investors (Pro only)

Seed 2024-06-24

$10.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

No team data available

Team information is not yet available for this company

Recent News

EpilepsyGTx Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised